Overview

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Collaborator:

Genentech, Inc.

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel